The pharmaceutical company Pfizer, and its partner in the field of development at Biontech, announced today (Friday) that the vaccine for the corona virus from its products is more than 90 percent effective among children aged 11-5.
These are the first official findings from a study conducted by the company, with the aim of enabling extensive vaccination of children against the corona virus.
The US Food and Drug Administration (FDA) announced the submission of the study's findings, and released a summary of the company's conclusions as a prelude to the organization's first meeting of the organization's expert council, which will decide whether to recommend approving vaccine use.
According to the company's findings, the vaccine is 90 percent effective against the onset of symptoms of coronary heart disease, and no serious side effects or cases of myocarditis have been detected, which have been previously linked to the administration of the vaccine.
The vaccine dose tested by the company is ten micrograms per injection, a third of the usual dose in adults.
The company claims that the size of the dose has been reduced in order to avoid side effects and because children have developed a sufficient level of antibodies.
"Accelerate the rate of immunization in poor countries"
Meanwhile, yesterday the World Health Organization warned that the corona "will be dragged into the second half of 2022" due to the slow rate of immunization in third world countries.
In an interview with the British Broadcasting Authority, Dr Bruce Eyalwood, a senior member of the United Nations World Health Organization, said: "We must accelerate the rate of immunization in poor countries, or this epidemic will last a year longer than it should."